EPISODE · Jan 10, 2024 · 1H 9M
Episode 83
from Biotech Hangout · host Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Guest host Nick Shipley, Bio’s policy expert joins Daphne Zohar, Brad Loncar, Mike Yee and Yaron Werber on this week’s Biotech Hangout. The group discusses policy affecting biotech, including march-in rights, PBMs, IRA and FTC involvement plus bipartisan initiatives like the Orphan Cures Act. They also discuss the state of the XBI and industry sentiment, Bluebird Bio’s setbacks following FDA approval and Pfizer’s stock after its 2024 forecast revenue. They cover data from Vertex, Icosavax, Arcellx and Legend, plus several ADC deals including Bristol Meyers Squibb, SystImmune, C4 Therapeutics, Merck, Nona Biosciences and Pfizer. Other topics include updates from ASH, the new Amgen CSO plus the group shares their thoughts on what to expect in 2024. *This episode aired on December 15, 2023
NOW PLAYING
Episode 83
No transcript for this episode yet
Similar Episodes
May 12, 2026 ·36m
May 11, 2026 ·11m
May 11, 2026 ·34m
May 11, 2026 ·38m